Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

The projected decline in PPLPHARMA's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 0.00000
forwardPE 75.42517
debtToEquity 60.08300
earningsGrowth 0.00000
revenueGrowth -0.02900
grossMargins 0.60984
operatingMargins -0.00795
trailingEps -1.24000
forwardEps 2.19383

PPLPHARMA's forward PE is elevated, which may cap future price gains and even lead to a price correction. This overvaluation risk highlights the importance of considering this metric carefully in combination with other fundamental indicators to evaluate the stock properly.
PPLPHARMA's low earnings and revenue growth suggest shrinking profits are likely. This could reflect broader financial struggles, signaling that the company might face difficulties in sustaining its profitability.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

PPLPHARMA's price projections have been revised downward over time, reflecting a shift in sentiment among analysts. The steady decline in projections points to a more cautious outlook on the company's future performance.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


Analysts have shown a buy bias for Piramal Pharma Limited, marking it as a favorable investment option. This could inspire investors to see Piramal Pharma Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.